Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Cash & Current Investments (2018 - 2026)

Exagen filings provide 9 years of Cash & Current Investments readings, the most recent being $21.5 million for Q1 2026.

  • On a quarterly basis, Cash & Current Investments rose 92.18% to $21.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $21.5 million, a 92.18% increase, with the full-year FY2025 number at $32.2 million, up 46.22% from a year prior.
  • Cash & Current Investments hit $21.5 million in Q1 2026 for Exagen, down from $32.2 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $89.8 million in Q1 2022 to a low of $11.2 million in Q1 2025.
  • Median Cash & Current Investments over the past 5 years was $31.5 million (2023), compared with a mean of $39.5 million.
  • Biggest five-year swings in Cash & Current Investments: tumbled 59.0% in 2025 and later soared 92.18% in 2026.
  • Exagen's Cash & Current Investments stood at $62.4 million in 2022, then crashed by 41.51% to $36.5 million in 2023, then tumbled by 39.62% to $22.0 million in 2024, then surged by 46.22% to $32.2 million in 2025, then plummeted by 33.23% to $21.5 million in 2026.
  • The last three reported values for Cash & Current Investments were $21.5 million (Q1 2026), $32.2 million (Q4 2025), and $35.7 million (Q3 2025) per Business Quant data.